German biotech Leukocare opens in the US

Leukocare, a German biotechnology company specialising in formulation development for biologics, viral vectors and vaccines, has opened development labs in Milford, USA. Its headquarters will remain in Martinsried/Munich, Germany.

Being present in the US market offers the opportunity to collaborate closely with customers and partners on tailor-made solutions in the field of drug product formulation development for biopharmaceuticals and advanced therapy medicinal products (ATMP). An in-house biostatistics team adds to more than fifteen years of experience in this area by using best-in-class algorithms and deep learning to provide individually designed solutions in less time.

Leukocare´s US offices and laboratories are up and running and the team on both sides of the Atlantic will collaborate closely to serve global clients. The offices and laboratories are located at Rentschler Biopharma´s Milford premises, a Contract Development and Manufacturing Organization (CDMO). Leukocare and Rentschler Biopharma have been sharing a global strategic alliance since 2017 to offer integrated best-in-class formulation development services considered at every step of the biopharmaceutical value chain.

Michael Scholl, Chief Executive Officer at Leukocare, commented, “I am delighted to announce the opening of Leukocare´s US site today. The company´s outstanding development over the last few years led to our desire of establishing a presence in the largest pharmaceuticals market worldwide. This strategic step enables us to be even closer to both our US and global customers and to better understand and serve their needs. Furthermore, the existing infrastructure of Rentschler in Milford – that we will partially make use of – allows us to start operations without any delay and thus makes Milford the perfect choice for our newly established US site. We therefore will continue to pursue our strategy of pushing boundaries of biopharmaceutical product development by combining innovative biostatistics, artificial intelligence and vast formulation expertise with first-class analytics.”

Image credit: Science in HD



Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free